LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms,… Read more
Market Cap & Net Worth: LABIANA HEALTH S.A.EO-10 (8RK)
LABIANA HEALTH S.A.EO-10 (F:8RK) has a market capitalization of $41.14 Million (€40.08 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #27744 globally and #3033 in its home market, demonstrating a 30.90% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LABIANA HEALTH S.A.EO-10's stock price €5.55 by its total outstanding shares 7221255 (7.22 Million).
LABIANA HEALTH S.A.EO-10 Market Cap History: 2022 to 2026
LABIANA HEALTH S.A.EO-10's market capitalization history from 2022 to 2026. Data shows growth from $22.53 Million to $41.14 Million (26.05% CAGR).
LABIANA HEALTH S.A.EO-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LABIANA HEALTH S.A.EO-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8RK by Market Capitalization
Companies near LABIANA HEALTH S.A.EO-10 in the global market cap rankings as of March 19, 2026.
Key companies related to LABIANA HEALTH S.A.EO-10 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
LABIANA HEALTH S.A.EO-10 Historical Marketcap From 2022 to 2026
Between 2022 and today, LABIANA HEALTH S.A.EO-10's market cap moved from $22.53 Million to $ 41.14 Million, with a yearly change of 26.05%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €41.14 Million | +26.71% |
| 2025 | €32.47 Million | +62.22% |
| 2024 | €20.01 Million | +128.81% |
| 2023 | €8.75 Million | -61.18% |
| 2022 | €22.53 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of LABIANA HEALTH S.A.EO-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.14 Million USD |
| MoneyControl | $41.14 Million USD |
| MarketWatch | $41.14 Million USD |
| marketcap.company | $41.14 Million USD |
| Reuters | $41.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.